Peptide Tools to Study EBV
Epstein–Barr virus (EBV or Human gammaherpesvirus 4) is one of the most common viruses in humans. EBV causes infectious mononucleosis but is also associated with various lymphoproliferative diseases, malignancies and conditions associated with HIV as well as some childhood disorders and an elevated risk of developing certain autoimmune diseases. About 200,000 cancer cases per year are attributed to EBV and studies suggest that EBV as the leading cause of multiple sclerosis.
Epstein-Barr virus belongs to the family of Herpesviridae. It is known as the cause of infectious mononucleosis and infects immune and epithelial cells. Being able to establish a long-term, latent infection in human memory B cells, it is prevalent in the adult population (worldwide 90%).
The double standed virus DNA is protected by an icosahedral nucleocapsid, which is surrounded by a protein tegument and an envelope of glycoproteins and lipids.
EBV is associated with a range of human diseases and cancers
- Hodgkin’s and Burkitt’s lymphoma, hemophagocytic lymphohistiocytosis
- Nasopharyngal and gastric carcinoma
- Main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients
- Increases the risk of certain autoimmune diseases, e.g. lupus erythematosus, rheumatoid arthritis and multiple sclerosis
- Plays a role in the development of chronic fatigue syndrome (CFS)
- HIV associated diseases (hairy leukoplakia, central nervous system lymphomas)
- Alice in Wonderland syndrome and acute cerebellar ataxia in children
The latent EBV Antigens
During latent infection EBV expresses only a small number of viral genes. Three major types of latency can be differentiated by their distinct expression patterns of these genes and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection.
Depending on the latency (I -III) program EBV expresses a subset of these proteins: EBNA-1, EBNA-2, EBNA-3A,EBNA-3B, EBNA-3C, EBNA-LP, LMP-1, LMP-2A, LMP-2B and EBER.
JPT's EBV Peptide Formats
Cellular Immune Response Profiling
PepMix™ Peptide Pools
- Antigen specific stimulation of T-cells
- Immune monitoring of high-risk patients
- Qualification of immunodominant antigens
- Validating clinical T-cell assays
- PepMix™ Collection EBV include 13 immunodominant antigens in one plate for fast and economic immune response profiling
- EBV PepMix™ Peptide Pools for single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340
- Custom PepMix™ Peptide Pools for your specific needs!
- T-cell assays in
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
Humoral Immune Response Profiling
PepStar Peptide Microarrays
- Ready-made peptide microarrays displaying overlapping peptides through single immunodominant antigens: BARF1, BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2, GP350/340.
- Immune monitoring of humoral responses
- Profiling of EBV specific samples or antibodies
- Evaluation of co-infection
- Detection of epitopes and epitope spreading
- PepStar™ Antigen Collection: Combines overlapping peptides for all the proteins above on one microarray for optimal coverage of the most important antigens in a single experiment.
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored peptide microarray.
Our tailored Peptide ELISA plates are offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.